Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
other
Where this comes from
- Record sourced from PubMed, PMID 33090877.
- Also identified by DOI 10.7326/M20-6169 and PMC identifier 7596738.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and comparison of the efficacy of these vaccines, a general set of clinical endpoints is proposed, along with considerations to guide the selection of the primary endpoints on the basis of clinical and statistical reasoning. The plausibility that vaccine protection against symptomatic COVID-19 could be accompanied by a shift toward more SARS-CoV-2 infections that are asymptomatic is highlighted, as well as the potential implications of such a shift.
Medical subject headings
- COVID-19
- COVID-19 Vaccines
- Randomized Controlled Trials as Topic